Fundraising FoxSR One Capital Management — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
BiotechPalo Alto, US
James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in
BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in
Co-investorsFrazier Life SciencesLongitude CapitalOrbiMed
Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.
Biotech
Co-investorsRA CapitalVida Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.